Flusource
Search
Why Vaccinate
Economic Burden
Updated ACIP Guidelines
Practice Support Materials
Find Distributors
Additional Resources
For Pharmacists
For Employers
For Consumers
VIP
Send to a Friend Send to a Friend
Change font sizeChange font size
For U.S.Healthcare Professionals Only
Non-U.S. residents
Novartis
Learn About Novartis
Health Care Professional

Economic Burden

The Economic Burden of Influenza

Influenza causes considerable economic burden and a significant strain on U.S. healthcare services and medical resources:

  • Direct medical costs are on average estimated to be as high as $10.4 billion annually1
  • The total annual economic burden, including indirect costs and lost productivity, is reported to be $87.1 billion1
  • During influenza outbreaks, visits to family care physicians and internal medicine specialists can increase between 150 and 450 percent2
  • Using a pharmacoeconomic model (2003 values):
    • The average cost of outpatient care for influenza (including office visits, tests and medications), ranged from $95 for low-risk patients to $733 for those at high-risk1
  • In the U.S., the economic impact of an influenza epidemic has been estimated to be between $89.7 billion and 209.4 billion, assuming attack rates of 15% and 35%, respectively.1
  • Lost productivity is also a major consequence of widespread influenza epidemic. For instance, in the U.S. in 1996, influenza epidemic was estimated to result in 192 million bed-days, 70 million work-loss days, and 38 million school-loss days, and 346 million restricted-activity days.2 In 2003 dollars, the extent of lost earnings due to lost productivity accounted for $16.3 billion annually.1
  • Economic analysis of the results of a double-blind, placebo-controlled clinical trial of vaccination against influenza showed that absenteeism from work due to upper respiratory illness was reduced by 43 percent, absenteeism due to all illnesses by 36 percent, and visits to physicians' offices for upper respiratory illness by 44 percent. Combined cost savings were estimated at $46.85 per person vaccinated (1994 values)3

References:

  1. Molinari NA, Ortega-Sanchez I, Messonier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007 In press.
  2. Mauskopf JA, Cates SC, Griffin AD. A pharmacoeconomic model for the treatment of influenza. Pharmacoeconomics. 1999;16(suppl 1):73-84.
  3. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995:333:889-893.
Order
Novartis

Influenza vaccination may not prevent the disease in 100% of individuals. Persons should consult their healthcare provider to determine if they have a condition that precludes them from receiving the vaccine. All vaccines have side effects. The most common side effects of influenza vaccines include local reactions and mild general symptoms.

Why Vaccinate? |  Economic Burden  |  Updated ACIP Guidelines  |  Practice Support Materials  |  Find Distributors|  Additional Resources

For Consumers  | For Pharmacists  |  For Employers

FluSource.com has been developed by Novartis Vaccines as part of the company's commitment to individual and public health.

Full Prescribing Information  |  Contact Us  |  Site Map

This site is sponsored by Novartis Vaccines and Diagnostics, Inc.
Use of this website is governed by the Terms of Use and Privacy Statement.
Copyright © 2008 Novartis Vaccines and Diagnostics, Inc. All rights reserved.